1. Home
  2. BNBX vs HCWB Comparison

BNBX vs HCWB Comparison

Compare BNBX & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNBX

Applied DNA Sciences Inc.

N/A

Current Price

$0.52

Market Cap

3.6M

ML Signal

N/A

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$0.37

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNBX
HCWB
Founded
1983
2018
Country
United States
United States
Employees
26
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
2.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BNBX
HCWB
Price
$0.52
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
375.2K
431.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,099,750.00
Revenue This Year
$253.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.25
52 Week High
$6.17
$17.80

Technical Indicators

Market Signals
Indicator
BNBX
HCWB
Relative Strength Index (RSI) 30.56 42.18
Support Level N/A $0.25
Resistance Level $0.82 $0.78
Average True Range (ATR) 0.08 0.04
MACD -0.00 0.02
Stochastic Oscillator 12.23 57.16

Price Performance

Historical Comparison
BNBX
HCWB

About BNBX Applied DNA Sciences Inc.

BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: